Many new medicines that work directly on the body’s immune system are being studied for the treatment of COPD. In 2024, Dupixent became the first of these medicines to be approved for COPD.

Fact checked by Jennifer Klump Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD ...

Oct. 2, 2024 — The FDA has approved Regeneron and Sanofi’s drug Dupixent for patients with COPD (chronic obstructive pulmonary disease).Marking the sixth indication for the drug, the approval ...

The FDA cleared Dupixent for people with COPD who are also using inhaled COPD medications yet still have too many eosinophils. An important part of the immune system, eosinophils are a type of ...

Dupixent ® (dupilumab) approved in the US as the first-ever biologic medicine for patients with COPD. News release. Regeneron Pharmaceuticals, Inc. Accessed September 27, 2024.

Dupixent is an antibody designed to block IL-13 and IL-4, two signaling pathways that drive inflammation. In COPD, the drug is intended to specifically address type 2 inflammation, an excessive ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

The companies began testing Dupixent in COPD in 2018, taking a risk by going straight to phase 3. When interim results for the BOREAS trial were positive, Sanofi kicked off a second phase 3 trial ...

About the Dupixent COPD phase 3 study program. BOREAS and NOTUS were replicate, randomized, phase 3, double-blind, placebo-controlled studies that evaluated the efficacy and safety of Dupixent in ...

Dupixent®, or dupilumab, was the first biologic medicine approved for COPD in the U.S., and targets IL-4 and IL-13 signaling, which are two of the key immune molecules involved in a type 2 ...

Chronic obstructive pulmonary disease (COPD): One dose of Dupixent every other week The pediatric dosages of Dupixent may vary for certain conditions based on a child’s age, as outlined below.